| Literature DB >> 35262033 |
Per Kristian Knudsen1, Andreas Lind2, Ingvild Klundby2, Susanne Dudman2,3.
Abstract
Background: Measures to reduce spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) during the Covid-19 pandemic 2020-2021 may impact other microbiological agents. We aimed to investigate the incidence of infectious diseases and the incidence of viruses other than SARS-CoV-2 amongst children at The Department of Paediatric and Adolescent Medicine, Oslo University Hospital, Norway during 2020-2021 compared to previous years.Entities:
Keywords: Covid-19; Enterovirus; Epidemiology; Human metapneumovirus (HMPV); Norovirus; Paediatric infectious diseases; Respiratory syncytial virus (RSV); Rhinovirus, adenovirus; Rotavirus <PE-FRONTEND>; influenza virus
Year: 2021 PMID: 35262033 PMCID: PMC8692238 DOI: 10.1016/j.jcvp.2021.100060
Source DB: PubMed Journal: J Clin Virol Plus ISSN: 2667-0380
The total number of hospital contacts (outpatient contacts and hospitalisations) for patients 0–18 years with selected infectious disease diagnoses during 12 months periods (April 1st - March 31st) 2017–2018, 2018–2019 and 2019–2020 (the pre-pandemic period) and 2020–2021 (the Covid-19 pandemic period).
| ICD-10 diagnoses | Female sex | Mean (SD) age (years) | 2017–2018 | 2018–2019 | 2019–2020 | 2020–2021 | Difference 2017–2020 vs. 2020–2021 | p-value |
| J21 Acute bronchiolitis | 38.6% | 0.9 (1.7) | 357 | 513 | 274 | 40 | -90% | |
| J12 Viral pneumonia | 42.5% | 3.1 (3.3) | 151 | 117 | 145 | 15 | -89% | |
| J13+J14+J15 Bacterial pneumonia | 48.9% | 6.5 (5.4) | 50 | 63 | 108 | 35 | -53% | |
| A08 + A09 Gastroenteritis* | 40.6% | 3.6 (4.2) | 422 | 357 | 298 | 92 | -74% | |
| A85+A86+A87 Viral encephalitis/ meningitis* | 50.9% | 8.6 (6.6) | 15 | 23 | 17 | 4 | -78% | |
| N10 Pyelonephritis | 62.4% | 3.0 (4.4) | 190 | 141 | 153 | 119 | -26% | |
| M86 Osteomyelitis | 66.3% | 10.3 (4.9) | 48 | 82 | 102 | 99 | +28% | |
| A69.2 Lyme Borreliosis* | 53.9% | 10.8 (4.5) | 23 | 28 | 39 | 41 | +37% | |
| R56.0 Febrile seizures | 45.9% | 2.9 (2.4) | 106 | 95 | 101 | 45 | -55% |
* Either primary or secondary diagnosis code.
Proportion of nasopharyngeal samples positive for selected airway viruses, faecal samples positive for gastrointestinal viruses and samples from multiple specimens positive for enteroviruses during 12 months periods (April 1st - March 31st) 2017–2018, 2018–2019 and 2019–2020 (the pre-pandemic period) and 2020–2021 (the Covid-19 pandemic period).
| Sample specimen | 2017–2018 | 2018–2019 | 2019–2020 | 2020–2021 | p-value* | |
| RSV | NF | 322/3032 (10.6%) | 570/3072 (18.6%) | 247/2730 (9.0%) | 10/2102 (0.5%) | |
| Influenza virus A/B | NF | 316/3032 (10.4%) | 202/3072 (6.6%) | 213/2730 (7.8%) | 4/2102 (0.2%) | |
| HMPV | NF | 226/3032 (7.5%) | 32/3072 (1.0%) | 195/2730 (7.1%) | 0/2102 | |
| Rhinovirus | NF | 979/3032 (32.3%) | 1116/3072 (36.3%) | 992/2730 (36.3%) | 666/2102 (31.7%) | |
| Adenovirus | NF | 324/3032 (10.6%) | 349/3072 (11.3%) | 265/2730 (9.7%) | 190/2102 (9.0%) | |
| Rotavirus | F | 51/462 (11%) | 26/387 (6.7%) | 33/413 (8%) | 18/296 (6.1%) | |
| Adenovirus | F | 50/462 (10.8%) | 59/387 (15.2%) | 16/414 (3.9%) | 3/295 (1%) | |
| Norovirus | F | 69/571 (12.1%) | 63/540 (11.7%) | 66/537 (12.3%) | 11/332 (3.3%) | |
| Enterovirus | B, F, A, V, C, O | 131/653 (20.0%) | 185/775 (23.8%) | 200/956 (20.9%) | 20/569 (3.5%) |
* 2017-2020 vs. 2020-2021. NF: nasopharyngeal, F: faecal, B: blood, A: airways, V: vesicles, C: cerebrospinal fluid.
O: other unspecified specimens, RSV: Respiratory syncytial virus, HMPV: Human metapneumovirus.
Fig. 1Proportion of nasopharyngeal samples positive for Respiratory syncytial virus, influenza virus, Human metapneumovirus, rhinovirus and adenovirus, and proportion of faecal samples positive for rotavirus shown for four-week intervals during 12 months periods (April 1st - March 31st) 2017–2018, 2018–2019 and 2019–2020 (the pre-pandemic period) and 2020–2021 (the Covid-19 pandemic period).